Journal
Neuro-Oncology
Publication Date
11-2-2022
Volume
24
Issue
11
First Page
1935
Last Page
1949
Document Type
Open Access Publication
DOI
10.1093/neuonc/noac116
Rights and Permissions
Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro, Raju R Raval, George Ansstas, Joachim Baehring, Jennie W Taylor, Jerome Honnorat, Kevin Petrecca, Filip De Vos, Antje Wick, Ashley Sumrall, Solmaz Sahebjam, Ingo K Mellinghoff, Masashi Kinoshita, Mustimbo Roberts, Ruta Slepetis, Deepti Warad, David Leung, Michelle Lee, David A Reardon, Antonio Omuro, Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter, Neuro-Oncology, Volume 24, Issue 11, November 2022, Pages 1935–1949, https://doi.org/10.1093/neuonc/noac116. © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Recommended Citation
Lim, Michael; Ansstas, George; and et al., "Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter." Neuro-Oncology. 24, 11. 1935 - 1949. (2022).
https://digitalcommons.wustl.edu/oa_4/1010
Additional Links
Supplemental material is available for this article at publisher site.
